Zydus Lifesciences Limited: Business Overview, Financials & Competitive Analysis
Zydus Lifesciences Limited scores 7/10 on the AskCyborg Cyborg Score (Strong). Mid-tier Indian pharma leader with strong biosimilar capabilities and specialty portfolio expansion, though growing at a slower pace than the broader industry. Zydus reported Q3 2026 revenue of ₹68.6b, up 30% from Q3 2025, and Q2 2026 net income of ₹12.6b, up 38% from Q2 2025. Recent product launches.
What is Zydus Lifesciences Limited's industry? Zydus Lifesciences Limited (zyduslifesciences.com) operates in Generic Drugs. AskCyborg classifies Zydus Lifesciences Limited under Generic Drugs in its company registry.
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad. The group ranks 4th in the Indian pharmaceutical industry and oper...
Cyborg Score thesis
Mid-tier Indian pharma leader with strong biosimilar capabilities and specialty portfolio expansion, though growing at a slower...
Read the full analyst-debate transcript →Get the Latest Zydus Lifesciences Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeZydus Lifesciences Limited Overview
Pro stress-test →Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad. The group ranks 4th in the Indian pharmaceutical industry and operates across generic pharmaceuticals, biosimilars, vaccines, and consumer wellness with a strong global footprint in regulated markets.
Strategic Profile
Pro stress-test →The company's growth has been driven by an expanding specialty portfolio, strong India business growth, a robust product pipeline and value-accretive acquisitions. Zydus maintains India's largest biosimilar portfolio with more than 13 biosimilars developed and manufactured domestically. The company expects its India formulations business to outperform the pharmaceutical market by 200-400 basis points, positioning it as a competitive player in high-growth domestic and international segments.
Competitive Landscape
Pro stress-test →Key competitors include Torrent Pharmaceuticals, Mankind Pharma, Ajanta Pharma, Natco Pharma, and Glenmark Pharmaceuticals. Zydus differentiates through its large domestically developed biosimilar portfolio and expanding specialty pharmaceutical capabilities, though it faces strong competition from larger generics-focused peers in the Indian pharmaceutical market.
Industry Context
Zydus Lifesciences Limited operates in Generic Drugs.
Key facts
Founded: 1952 · Headquarters: Ahmedabad, India · Employees: 29,000 · Revenue: $2.93B (trailing twelve months) · Market cap: ₹1,10,826 crore (~$13.3B USD as of June 2026)